209 related articles for article (PubMed ID: 26507833)
1. Drug-Induced Progressive Multifocal Leukoencephalopathy: A Comprehensive Analysis of the WHO Adverse Drug Reaction Database.
Melis M; Biagi C; Småbrekke L; Nonino F; Buccellato E; Donati M; Vaccheri A; Motola D
CNS Drugs; 2015; 29(10):879-91. PubMed ID: 26507833
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced progressive multifocal leukoencephalopathy: a case/noncase study in the French pharmacovigilance database.
Colin O; Favrelière S; Quillet A; Neau JP; Houeto JL; Lafay-Chebassier C; Pérault-Pochat MC;
Fundam Clin Pharmacol; 2017 Apr; 31(2):237-244. PubMed ID: 27736027
[TBL] [Abstract][Full Text] [Related]
3. Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS).
Schmedt N; Andersohn F; Garbe E
Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1216-20. PubMed ID: 22821419
[TBL] [Abstract][Full Text] [Related]
4. Progressive multifocal leukoencephalopathy analyzed using the Japanese Adverse Drug Event Report database.
Sakurai S; Maezawa M; Nakao S; Hirofuji S; Miyasaka K; Yamashita M; Matsui K; Nishida S; Kobayashi R; Iguchi K; Hayashi Y; Suzuki A; Nakamura M
J Neurol Sci; 2023 Dec; 455():122789. PubMed ID: 37984106
[TBL] [Abstract][Full Text] [Related]
5. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system.
Raisch DW; Rafi JA; Chen C; Bennett CL
Expert Opin Drug Saf; 2016 Aug; 15(8):1003-11. PubMed ID: 27268272
[TBL] [Abstract][Full Text] [Related]
6. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents.
Piccinni C; Sacripanti C; Poluzzi E; Motola D; Magro L; Moretti U; Conforti A; Montanaro N
Eur J Clin Pharmacol; 2010 Feb; 66(2):199-206. PubMed ID: 19838692
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab.
Vermeer NS; Straus SM; Mantel-Teeuwisse AK; Hidalgo-Simon A; Egberts AC; Leufkens HG; De Bruin ML
Clin Pharmacol Ther; 2015 Nov; 98(5):542-50. PubMed ID: 26347128
[TBL] [Abstract][Full Text] [Related]
8. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
[TBL] [Abstract][Full Text] [Related]
9. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies.
Molloy ES; Calabrese LH
Arthritis Rheum; 2012 Sep; 64(9):3043-51. PubMed ID: 22422012
[TBL] [Abstract][Full Text] [Related]
10. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
Carson KR; Evens AM; Richey EA; Habermann TM; Focosi D; Seymour JF; Laubach J; Bawn SD; Gordon LI; Winter JN; Furman RR; Vose JM; Zelenetz AD; Mamtani R; Raisch DW; Dorshimer GW; Rosen ST; Muro K; Gottardi-Littell NR; Talley RL; Sartor O; Green D; Major EO; Bennett CL
Blood; 2009 May; 113(20):4834-40. PubMed ID: 19264918
[TBL] [Abstract][Full Text] [Related]
11. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
12. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients.
Kothary N; Diak IL; Brinker A; Bezabeh S; Avigan M; Dal Pan G
J Am Acad Dermatol; 2011 Sep; 65(3):546-551. PubMed ID: 21514689
[TBL] [Abstract][Full Text] [Related]
13. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.
Chahin S; Berger JR
J Neurovirol; 2015 Dec; 21(6):623-31. PubMed ID: 25404234
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population.
Eng PM; Turnbull BR; Cook SF; Davidson JE; Kurth T; Seeger JD
Neurology; 2006 Sep; 67(5):884-6. PubMed ID: 16966559
[TBL] [Abstract][Full Text] [Related]
15. Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in psoriasis patients.
Balak DMW; Hajdarbegovic E; Bramer WM; Neumann HAM; Thio HB
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1475-1482. PubMed ID: 28322482
[TBL] [Abstract][Full Text] [Related]
16. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.
Berger JR; Malik V; Lacey S; Brunetta P; Lehane PB
J Neurovirol; 2018 Jun; 24(3):323-331. PubMed ID: 29508305
[TBL] [Abstract][Full Text] [Related]
17. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
Rath L; Vijiaratnam N; Skibina O
Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
[TBL] [Abstract][Full Text] [Related]
18. Incidence of progressive multifocal leukoencephalopathy in patients without HIV.
Amend KL; Turnbull B; Foskett N; Napalkov P; Kurth T; Seeger J
Neurology; 2010 Oct; 75(15):1326-32. PubMed ID: 20938025
[TBL] [Abstract][Full Text] [Related]
19. Progressive multifocal leukoencephalopathy in patients with HIV infection.
Berger JR; Pall L; Lanska D; Whiteman M
J Neurovirol; 1998 Feb; 4(1):59-68. PubMed ID: 9531012
[TBL] [Abstract][Full Text] [Related]
20. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
Krämer J; Tenberge JG; Kleiter I; Gaissmaier W; Ruck T; Heesen C; Meuth SG
PLoS One; 2017; 12(4):e0174858. PubMed ID: 28406921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
